I'm LongbridgeAI, I can summarize articles.EQ504, a highly potent and selective oral AhR modulator, is advancing as a colon-targeted therapy for ulcerative colitis, addressing a large unmet need in a $12B+ global market. Strong preclinical and clinical validation, robust IP, and a solid financial position support progress toward key milestones, with Phase 1 initiation expected in Q4 2026.Original document: Equillium, Inc. [EQ] Slides Release — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
EQ504, a highly potent and selective oral AhR modulator, is advancing as a colon-targeted therapy for ulcerative colitis, addressing a large unmet need in a $12B+ global market. Strong preclinical and clinical validation, robust IP, and a solid financial position support progress toward key milestones, with Phase 1 initiation expected in Q4 2026.
Original document: Equillium, Inc. [EQ] Slides Release — Aug. 13 2026